Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | President & COO | March 06, 2025 | March 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date March 06, 2025 · Filed March 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2035-03-05 | Direct | 178,400 |
Reported balance
After 2025-03-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-06 · Grant · Acquired 178,400 · Balance 178,400 F1: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2025 Filed Mar 10, 2025 23:56 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 178,400 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0000950170-25-036683 · ownership.xml · derivative · entry 1 Kamal Fariborz · CIK 0001834020 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,400 Underlying: Common Stock · 178,400 shares Expires 2035-03-05 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $14.42 | $0.00 |
DisclosureSEC source: 0000950170-23-070012 · ownership.xml · derivative · entry 1 Kamal Fariborz · CIK 0001834020 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2033-12-10 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 01:23 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $20.24 | $0.00 |
DisclosureSEC source: 0001567619-23-003007 · doc1.xml · derivative · entry 1 Kamal Fariborz · CIK 0001834020 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-02-09 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company Read SEC document |
| September 23, 2022 Filed Sep 27, 2022 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $8.06 | $0.00 |
DisclosureSEC source: 0001567619-22-017847 · doc1.xml · derivative · entry 1 Kamal Fariborz · CIK 0001834020 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-09-22 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 23, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:40 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001567619-22-017099 · doc1.xml · derivative · entry 1 Kamal Fariborz · CIK 0001834020 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-08-31 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:39 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0001567619-22-002465 · doc1.xml · derivative · entry 1 Kamal Fariborz · CIK 0001834020 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:06 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $41.66 | $0.00 |
DisclosureSEC source: 0001567619-21-005968 · doc1.xml · derivative · entry 1 Kamal Fariborz · CIK 0001834020 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-07 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 8, 2021 (the "Vesting Commencement Date") while the grantee remains a service provider to the Company. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 22:40 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | PurchaseCommon Stock | 4,347 | $23.00 | $99,981.00 |
DisclosureSEC source: 0001567619-20-021288 · doc1.xml · nonDerivative · entry 1 Kamal Fariborz · CIK 0001834020 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,347 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.